DOCSLIB.ORG

Diabetes Medications Dosing Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diabetes Medications Dosing Guide DIABETES MEDICATIONS DOSING GUIDE THE FOLLOWING TABLE DETAILS DOSING RECOMMENDATIONS FOR DIABETES TREATMENT AGENTS Dosing Adjust- A1C Lowering Class Generic Name Brand Names Initial Dose1 Maintenance Dose1 Max Dose1 ments1,2 Notes 3-5 Potential 2 Increase in 500mg 500mg BID or increments or Up to 2550mg Metformin Glucophage® 850mg Daily 850mg every 2 daily weeks Metformin 1000 to 2000 mg Up to 2000mg Glucophage XR® 500mg daily Low risk of Extended Release daily daily hypoglycemia Contraindicated Metformin 1000 to 2500mg Up to 2500mg Biguanides Fortamet® 500-1000mg daily for patients with Gastrointestinal Extended Release daily daily renal insufficiency side effects Metformin 500 to 2000mg Up to 2000mg Glumetza® 500mg daily First line treatment Extended Release daily daily Increase in 500mg Metformin 500mg BID or increments or Up to 2550mg Riomet® solution 850mg Daily 850mg every 2 daily weeks 1-1.5% 100 to 250 mg Up to 1000mg Tolazamide Tolinase® daily with the first Notable daily meal of the day hypoglycemia risk Sulfonylureas lose effectiveness No dosing due to their adjustments mechanism required. Initial of action. hepatic and Effectiveness is Sulfonylureas renal impairment lost as pancreas Tolbutamide Orinase® 1 to 2 g daily Up to 3g daily dosing should be damage conservative. progresses in some diabetics 8 Loses effectiveness and causes weight gain Dosing A1C Lowering Class Generic Name Brand Names Initial Dose1 Maintenance Dose1 Max Dose1 Adjustments1,2 Notes Potential 2 Long half life, can be as long as 72 hours Should be avoided Notable Chlorpropamide* Diabinese® 250mg daily 100 to 500mg daily Up to 750mg daily in those with CrCl hypoglycemia risk <50mg/dl Loses effectiveness and causes weight gain No dosing adjustments required Titrate in 2.5 to Glipizide Glucotrol® 5mg daily Up to 40mg daily 5mg increments Doses over 10mg/day shown no increased effectiveness No dosing adjustments Higher risk of required hypoglycemia Sulfonylureas Sulfonylureas Dosing should considered 1-1.5% (continued) be titrated conservatively second line by the Glipizide Glucotrol XL® 5mg daily 5 to 10mg daily Up to 20mg daily in those with ADA and add on hepatic or renal therapy by AACE impairments May cause Doses over weight gain 10mg/day shown Glyburide and no increased chlorpropamide effectiveness are considered No dosing high risk increase in 1 to 2 Glimepiride Amaryl® 1 to 2 mg daily Up to 8mg daily adjustments medications due mg increments required to increased risk of hypoglycemia Doses over 10mg/day shown Up to 5mg daily no increased initially effectiveness3 Glyburide* Diabeta® 2.5 to 5mg daily 1.25 to 20mg daily Up to 20mg daily Should not be as maintenance used in patients with CrCl <50ml/min - 2 - Dosing A1C Lowering Class Generic Name Brand Names Initial Dose1 Maintenance Dose1 Max Dose1 Adjustments1,2 Notes Potential 2 Up to 3mg Glynase 0.75 to 12mg daily daily initially Glyburide* 1.5 to 3mg daily Doses over (Micronized)® or in split doses Up to 12mg daily 10mg/day shown as maintenance no increased effectiveness3 Higher risk of Should not be hypoglycemia Up to 5mg daily used in patients Sulfonylureas initially with CrCl considered Glyburide* Micronase® 2.5 to 5mg daily 1.25 to 20mg daily <50ml/min Up to 20mg daily second line by the as maintenance ADA and add on therapy by AACE Sulfonylureas May cause 1-1.5% (continued) weight gain Glyburide 1.25/ No dosing Glyburide / 2.5mg/500mg to Up to 20mg/ Glyburide and Glucovance® Metformin adjustments Metformin* 5mg/500mg BID 2000mg daily chlorpropamide 250mg BID required are considered Doses over high risk 10mg/day shown medications due no increased to increased risk of effectiveness3 hypoglycemia Glipizide 2.5mg/ Increase in Glipizide / Up to 20mg/ Contraindicated MetaglipTM Metformin increments of Metformin 2000mg daily for patients with 500mg BID 5mg/500mg renal insufficiency CrCl 20-40mL/min: 0.5mg BID to QID May double the Do not use with Repaglinide Prandin® Up to 16mg daily Start at 0.5 mg and prior to each meal dose weekly sulfonylureas titrate carefully Risk of hypoglycemia Meglitinides 0.5-1% Prandin is more effective than No dose 120mg TID prior Starlix at Nateglinide Starlix® adjustments to a meal lowering A1C required - 3 - Dosing A1C Lowering Class Generic Name Brand Names Initial Dose1 Maintenance Dose1 Max Dose1 Adjustments1,2 Notes Potential 2 Caution use in heart failure patients, black box warning. Increase 15mg Increased risk of Pioglitazone Actos® 15 or 30 mg daily Up to 45mg daily increments peripheral edema and weight gain Avandia- Rosiglitazone only available through Avandia- Rosiglitazone Medicines Patients with program If there is elevated insufficient fasting These agents 4mg daily or transaminases Rosiglitazone Avandia® plasma glucose Up to 8mg daily can be used in 2 doses or hepatic response, increase impairment with metformin to 8mg daily should avoid as second line this drug or as part of Thiazolidine- a multi-drug 0.5-1.4% diones Patients with CHF regimen class I or II should use no more than Caution use in 15mg daily heart failure Patients with CHF patients, black box class III or IV are warning. contraindicated Increased risk of peripheral edema and weight gain Pioglitazone 15/ Pioglitazone/ Actoplus Titrate based on Up to 45/ Contraindicated Metformin500 BID Metformin metformin® tolerability 2550mg daily for patients with or 15/850 daily renal insufficiency These agents can be used with metformin as second line or as part of a multi-drug regimen - 4 - Dosing A1C Lowering Class Generic Name Brand Names Initial Dose1 Maintenance Dose1 Max Dose1 Adjustments1,2 Notes Potential 2 Pioglitazone Pioglitazone/ Actoplus 15/ Metformin Titrate based Up to 45/ Metformin XR Metformin XR® 1000mg or on tolerability 2000mg daily 30/1000 daily Caution use in heart failure patients, black box warning Previously Increased risk of received peripheral edema rosiglitazone and weight gain 4mg daily: Rosiglitazone/ 2/500mg BID Contraindicated Avandamet® Metformin Patients with for patients with Previously elevated renal insufficiency received transaminases rosiglitazone or hepatic 8mg daily: impairment 4/500mg daily should avoid Thiazolidine- this drug diones 0.5-1.4% Patients with CHF (continued) Rosiglitazone class I or II should 4mg/ Increase by no use no more than Rosiglitazone/ Up to 8mg/ Avandaryl® glimiperide1mg more than 2mg 15mg daily Glimiperide 4mg daily Caution use in daily with increments Patients with CHF heart failure first meal class III or IV are patients, black box contraindicated warning Increased risk of Pioglitazone peripheral edema 30mg/ Glimiperide and weight gain 2mg or 30mg/ Avandia- 4mg daily Rosiglitazone Titrate gradually Pioglitazone/ Patients previously Up to 45mg/ only available Duetact® based on Glimiperide on glimepiride 8mg daily through Avandia- monotherapy tolerability Rosiglitazone or pioglitazone Medicines monotherapy have program the same initial dose - 5 - Dosing A1C Lowering Class Generic Name Brand Names Initial Dose1 Maintenance Dose1 Max Dose1 Adjustments1,2 Notes Potential 2 May be increased Up to 50mg TID for 25mg TID with to 50-100mg TID those <60kg No significant Acarbose Precose® the first bite of at four to eight weight changes each meal Up to 100mg TID week intervals for those >61kg ADA considers this medication third line May cause hypoglycemia, risk is higher when used with insulin Alpha- Dose titration or sulfonylureas Glucosidase will limit 0.5-0.8% inhibitors gastrointestinal Useful in side effects decreasing post-prandial glucose levels Contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial or complete 25mg TID 50mg TID up to 100mg intestinal Miglitol Glyset® with meals with meals TID daily obstruction - 6 - Dosing A1C Lowering Class Generic Name Brand Names Initial Dose1 Maintenance Dose1 Max Dose1 Adjustments1,2 Notes Potential 2 CrCl 30ml/min and Sitagliptin Januvia® 100mg daily dialysis: 25mg Risk of nasopharyngitis, upper respiratory tract infection CrCl <50ml/min Saxagliptin Onglyza® 2.5 to 5mg daily or strong CYP3a4 Risk of inhibitor: 2.5mg hypoglycemia Weight neutral Rare cases of DPP4-Inhibitors pancreatitis 0.5-1% ADA considers second line after metformin No renal dosing Should not be Linagliptin Tradjenta® 5mg daily necessary used with DM type 1 or for the treatment of diabetic ketoacidosis CrCl 30—59 ml/ min: 12.5 mg daily Alogliptan Nesina® 25mg daily CrCl < 30 ml/min: 6.25 mg daily - 7 - Dosing A1C Lowering Class Generic Name Brand Names Initial Dose1 Maintenance Dose1 Max Dose1 Adjustments1,2 Notes Potential 2 Previously on Metformin: Sitagliptin 50mg plus current dose of Metformin BID Previuosly on 850mg CrCl 30ml/min and Metformin / Metformin BID: Janumet® dialysis: 25mg of Sitagliptin Sitagliptin 50mg Sitagliptin plus 1000mg Metformin BID Risk of nasopharyngitis, Previuosly on upper respiratory Sitagliptin: tract infection Sitagliptin 50mg plus 500mg Risk of Metformin BID hypoglycemia Weight neutral Rare cases of DPP4-Inhibitors Previously on pancreatitis 0.5-1% (continued) Metformin: Sitagliptin 100mg ADA considers plus current dose second line after of Metformin daily CrCl 30ml/min and metformin Metformin / Janumet xr® dialysis: 25mg of Sitagliptin Previuosly on Should not be Sitagliptin 850mg Metformin used with DM BID: 2 tablets of type 1 or for Sitagliptin 50mg the treatment plus 1000mg of diabetic Metformin daily ketoacidosis Linagliptin 2.5mg/ No renal dosing Metformin 500mg necessary BID with meals Up to 2.5mg/ Metformin / Metformin should Jentadueto® Currently
Load more

Recommended publications
  • Metformin Plus Saxagliptin for Type 2 Diabetes
    Treatment evaluation Metformin plus saxagliptin for type 2 diabetes André J. Scheen Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman, University of Liège, Liège, Belgium Running title : Saxagliptin plus metformin Word count : Abstract : 148 Main text : 2404 Tables : 4 Figures : 0 Address for correspondence : Pr André J. SCHEEN Department of Medicine CHU Sart Tilman (B35) B-4000 LIEGE 1 BELGIUM Phone : 32-4-3667238 FAX : 32-4-3667068 Page 1 Email : andre.scheen @ chu.ulg.ac.be SUMMARY Metformin is considered as the first-line drug therapy for the management of type 2 diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors, by promoting insulin secretion and reducing glucagon secretion in a glucose-dependent manner, offer new opportunities for oral therapy after failure of metformin. Saxagliptin, a DPP-4 inhibitor, and metformin may be administered together, separately or in fixed-dose combination (FDC), either as saxagliptin added to metformin or as initial combination in drug-naive patients. Both compounds exert complementary pharmacodynamic actions leading to better improvement in blood glucose control (fasting plasma glucose, postprandial glucose, HbA1c) than either compound separately. Adding saxagliptin to metformin monthotherapy results in a consistent, sustained and safe reduction in HbA1c levels. Tolerance is excellent without hypoglycemia or weight gain. The combination saxaglitpin plus metformin may be used as first-line or second-line therapy in the management of type 2 diabetes, especially as a valuable alternative to the classical metformin-sulfonylurea combination. Key-words : DPP-4 inhibitor – Fixed-dose combination - Metformin – Saxagliptin - Type 2 diabetes mellitus Page 2 1.
    [Show full text]
  • Management of Diabetes Mellitus Standards of Care and Clinical Practice Guidelines
    WHO-EM/DIN6/E/G MANAGEMENT OF DIABETES MELLITUS STANDARDS OF CARE AND CLINICAL PRACTICE GUIDELINES Edited by Dr A.A.S. Alwan Regional Adviser, Noncommunicable Diseases WHO Regional Office for the Eastern Mediterranean WHO-EM/DIN6/E/G INTRODUCTION Available data from many countries of the Eastern Mediterranean Region (EMR) indicate that diabetes mellitus has become a problem of great magnitude and a major public health concern. Studies have demonstrated that, in some countries, diabetes affects up to 10% of the population aged 20 years and older. This rate may be doubled if those with impaired glucose tolerance (IGT) are also included. The manifestations of diabetes cause considerable human suffering and enormous economic costs. Both acute and late diabetic complications are commonly encountered. Long-term complications represented by cardiovascular diseases, cerebrovascular accidents, end-stage renal disease, retinopathy and neuropathies are already major causes of morbidity, disability and premature death in countries of this Region. The development of long-term complications is influenced by hyperglycaernia. Poor control of diabetes accelerates their progression. Thus, to prevent complications, good control of diabetes is essential and the management of diabetes should therefore aim to improve glycaemic control beyond that required to control its symptoms. Intensified therapy and maintaining near-normal blood glucose levels can result in considerable reduction in the risk of development of retinopathy, nephropathy and neuropathy. However, despite the high prevalence of diabetes and its complications and the availability of successful prevention strategies, essential health care requirements and facilities for self-care are often inadequate in this Region. Action is needed at all levels of health care and in the various aspects of diabetes care to bridge this gap and to improve health care delivery to people with diabetes.
    [Show full text]
  • LANTUS® (Insulin Glargine [Rdna Origin] Injection)
    Rev. March 2007 Rx Only LANTUS® (insulin glargine [rDNA origin] injection) LANTUS® must NOT be diluted or mixed with any other insulin or solution. DESCRIPTION LANTUS® (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as an injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. (See CLINICAL PHARMACOLOGY). LANTUS is produced by recombinant DNA technology utilizing a non- pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, it is 21A- B B Gly-30 a-L-Arg-30 b-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063. It has the following structural formula: LANTUS consists of insulin glargine dissolved in a clear aqueous fluid. Each milliliter of LANTUS (insulin glargine injection) contains 100 IU (3.6378 mg) insulin glargine. Inactive ingredients for the 10 mL vial are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 mcg polysorbate 20, and water for injection. Inactive ingredients for the 3 mL cartridge are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for injection. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. LANTUS has a pH of approximately 4. CLINICAL PHARMACOLOGY Mechanism of Action: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism.
    [Show full text]
  • Treatment of Diabetes Mellitus
    TREATMENT OF DIABETES MELLITUS DIABETES is a condition that affects how the body makes energy from food. Food is broken down into sugar (glucose) in the body and released into the blood. When the blood sugar level rises after a meal, insulin responds to let the sugar into the cells to be used as energy. In diabetes, the body either does not make enough insulin or it stops responding to insulin as well as it should. This results in sugar staying in the blood and leads to serious health problems over time. DIAGNOSIS OF DIABETES1 • A1C Test: Lab test measuring average blood sugar over past two to three months • Fasting Blood Sugar Test: Lab test measuring blood sugar after eight hours of no food or drink • Oral Glucose Tolerance Test (OGTT): Measures blood sugar before and two hours after drinking a specific sugary liquid • Random Blood Sugar Test: Measures blood sugar at a moment in time, without any kind of preparation (like fasting) FASTING BLOOD ORAL GLUCOSE TOLERANCE RANDOM BLOOD RESULT A1C TEST SUGAR TEST TEST SUGAR TEST Diabetes ≥ 6.5% ≥126 mg/dL ≥ 200 mg/dL ≥ 200 mg/dL Prediabetes 5.7 – 6.4% 100 – 125 mg/dL 140 – 199 mg/dL N/A Normal < 5.7% ≤99 mg/dL < 140 mg/dL N/A NON-DRUG TREATMENTS2 THERAPY COST WHAT TO EXPECT Diet (Mediterranean diet) and exercise (30 minutes a day, five days a week of moderate- Weight loss $-$$ intensity exercise); 7% weight loss decreases risk of diabetes3 Psychological intervention $$-$$$ Psychotherapy may reduce diabetic distress and improve glycemic control4,5 nationalcooperativerx.com PRESCRIPTION TREATMENTS
    [Show full text]
  • CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence On
    cancers Review CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology Emi Kawakita 1 , Daisuke Koya 2,3 and Keizo Kanasaki 1,3,* 1 Internal Medicine 1, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo 693-8501, Japan; [email protected] 2 Department of Diabetology & Endocrinology, Kanazawa Medical University, Uchinada 920-0293, Japan; [email protected] 3 Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Uchinada 920-0293, Japan * Correspondence: [email protected]; Tel.: +81-853-20-2183 Simple Summary: Dipeptidyl peptidase (DPP)-4 inhibitor is widely used for type 2 diabetes. Al- though DPP-4/CD26 has been recognized as both a suppressor and inducer in tumor biology due to its various functions, how DPP-4 inhibitor affects cancer progression in diabetic patients is still unknown. The aim of this review is to summarize one unfavorable aspect of DPP-4 inhibitor in cancer-bearing diabetic patients. Abstract: DPP-4/CD26, a membrane-bound glycoprotein, is ubiquitously expressed and has diverse biological functions. Because of its enzymatic action, such as the degradation of incretin hormones, DPP-4/CD26 is recognized as the significant therapeutic target for type 2 diabetes (T2DM); DPP- 4 inhibitors have been used as an anti-diabetic agent for a decade. The safety profile of DPP-4 inhibitors for a cardiovascular event in T2DM patients has been widely analyzed; however, a clear association between DPP-4 inhibitors and tumor biology is not yet established. Previous preclinical Citation: Kawakita, E.; Koya, D.; Kanasaki, K.
    [Show full text]
  • Insulin Aspart Sanofi, If It Is Coloured Or It Has Solid Pieces in It
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Insulin aspart Sanofi 100 units/ml solution for injection in vial Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution contains 100 units insulin aspart* (equivalent to 3.5 mg). Insulin aspart Sanofi 100 units/ml solution for injection in vial Each vial contains 10 ml equivalent to 1,000 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Each cartridge contains 3 ml equivalent to 300 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen Each pre-filled pen contains 3 ml equivalent to 300 units insulin aspart. Each pre-filled pen delivers 1-80 units in steps of 1 unit. *produced in Escherichia coli by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless, aqueous solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. 4.2 Posology and method of administration Posology The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
    [Show full text]
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • DESCRIPTION Tolazamide Is an Oral Blood-Glucose-Lowering Drug of the Sulfonylurea Class
    TOLAZAMIDE- tolazamide tablet PD-Rx Pharmaceuticals, Inc. ---------- DESCRIPTION Tolazamide is an oral blood-glucose-lowering drug of the sulfonylurea class. Tolazamide is a white or creamy-white powder very slightly soluble in water and slightly soluble in alcohol. The chemical name is 1-(Hexahydro-1 H-azepin-1-yl)-3-( p-tolylsulfonyl)urea. Tolazamide has the following structural formula: Each tablet for oral administration contains 250 mg or 500 mg of tolazamide, USP and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. CLINICAL PHARMACOLOGY Actions Tolazamide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which tolazamide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in type II diabetic patients, the blood glucose-lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonylurea hypoglycemic drugs. Some patients who are initially responsive to oral hypoglycemic drugs, including tolazamide tablets, may become unresponsive or poorly responsive over time. Alternatively, tolazamide tablets may be effective in some patients who have become unresponsive to one or more other sulfonylurea drugs. In addition to its blood glucose-lowering actions, tolazamide produces a mild diuresis by enhancement of renal free water clearance. Pharmacokinetics Tolazamide is rapidly and well absorbed from the gastrointestinal tract. Peak serum concentrations occur at 3 to 4 hours following a single oral dose of the drug.
    [Show full text]
  • Clinical Use of Hemoglobin A1c to Improve Diabetes Management
    PRACTICAL POINTERS Clinical Use of Hemoglobin A1c to Improve Diabetes Management Alan M. Delamater, PhD, ABPP or more than 25 years, the hemo- one recent study conducted in Norway6 A1C values. Only 14% of the youths globin A1c (A1C) test has been revealed that the majority (82.6%) of were able to accurately describe the A1C Fthe most widely accepted out- 201 adult patients with type 1 diabetes test. Just 11, 7.8, and 7.8% correctly come measure for evaluating glycemic knew what their last A1C was, and most identified the A1C ranges for good, fair, control in individuals with diabetes. patients (90%) knew what a satisfactory and poor glycemic control, respectively. The test provides an index of a patient’s A1C value would be. But a significant Very few youths (1.6–3.2%) knew the average blood glucose level during the number of patients (42%) reported they blood glucose values corresponding to past 2–3 months1 and is considered to had low knowledge of A1C testing in specific A1C results. Only a small num- be the most objective and reliable general. Furthermore, 25% of patients ber of youths correctly estimated the measure of long-term metabolic con- did not think that treatment intensifica- short- and long-term risks associated trol.2,3 The Diabetes Control and tion should occur at an A1C value of with A1C values of 7 and 12%. In this Complications Trial established that 10%. sample, there was a significant lack of maintaining A1C levels as close as pos- A recent cross-sectional study knowledge concerning the meaning and sible to the normal range results in con- examined the relationship between implications of the A1C test.
    [Show full text]
  • The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: a Systematic Review
    SYSTEMATIC REVIEW published: 14 June 2021 doi: 10.3389/fgene.2021.675053 The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review Assefa M. Baye 1, Teferi G. Fanta 1, Moneeza K. Siddiqui 2 and Adem Y. Dawed 2* 1 Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia, 2 Division of Population Health and Genomics, Ninewells Hospital and School of Medicine, University of Dundee, Dundee, United Kingdom Background: Adverse drug reactions (ADR) are a major clinical problem accounting for significant hospital admission rates, morbidity, mortality, and health care costs. One-third of people with diabetes experience at least one ADR. However, there is notable interindividual heterogeneity resulting in patient harm and unnecessary medical costs. Genomics is at the forefront of research to understand interindividual variability, and there are many genotype-drug response associations in diabetes with inconsistent findings. Here, we conducted a systematic review to comprehensively examine and synthesize the effect of genetic polymorphisms on the incidence of ADRs of oral glucose-lowering drugs in people with type 2 diabetes. Edited by: Celine Verstuyft, Methods: A literature search was made to identify articles that included specific Université Paris-Saclay, France results of research on genetic polymorphism and adverse effects associated with Reviewed by: oral glucose-lowering drugs. The electronic search was carried out on 3rd October Zhiguo Xie, 2020, through Cochrane Library, PubMed, and Web of Science using keywords and Central South University, China Vera Ribeiro, MeSH terms. University of Algarve, Portugal Result: Eighteen articles consisting of 10, 383 subjects were included in this review.
    [Show full text]
  • Think Medicines!
    Think Issue 13 August 2016 MHRA Drug Safety SGLT2 inhibitors: updated advice on the risk of diabetic Medicines!Updates can be found ketoacidosis (DKA) at the following link. The MHRA are advising health care professionals to test for raised ketones in patients with ketoacidosis symptoms, who are taking SGLT2 inhibitors even if New higher strength Humalog® plasma glucose levels are near-normal. SGLT2 inhibitors include: Canagliflozin, 200 units/ml KwikPen™ Dapagliflozin and Empagliflozin. Serious, life-threatening, and fatal cases of In order to minimize medication DKA have been reported in patients taking an SGLT2 inhibitor. In several cases, errors. blood glucose levels were only moderately elevated (e.g. <14mmol/L) Insulin lispro 200 units/ml representing an atypical presentation for DKA, which could delay diagnosis and solution for injection should treatment. ONLY be administered using the Advice for health Care Professionals: Humalog 200 units/ml pre-filled Inform patients of the signs of diabetic ketoacidosis (DKA) and advise them to pen (KwikPen). seek immediate medical advice if they develop any of these symptoms (e.g. When switching from one rapid weight loss, feeling sick or being sick, stomach pain, fast and deep Humalog strength to another, breathing, sleepiness, a sweet smell to the breath, a sweet or metallic taste in the dose does not need to be the mouth, or a different odour to urine or sweat). converted. Unnecessary dose Discuss the risk factors of DKA with patients. conversion may lead to under/ Discontinue treatment with the SGLT2 inhibitor immediately if DKA is over dosing and resultant hyper/ suspected or diagnosed.
    [Show full text]
  • Supplementary Material
    Supplementary material Table S1. Search strategy performed on the following databases: PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL). 1. Randomi*ed study OR random allocation OR Randomi*ed controlled trial OR Random* Control* trial OR RCT Epidemiological study 2. sodium glucose cotransporter 2 OR sodium glucose cotransporter 2 inhibitor* OR sglt2 inhibitor* OR empagliflozin OR dapagliflozin OR canagliflozin OR ipragliflozin OR tofogliflozin OR ertugliflozin OR sotagliflozin OR sergliflozin OR remogliflozin 3. 1 AND 2 1 Table S2. Safety outcomes of empagliflozin and linagliptin combination therapy compared with empagliflozin or linagliptin monotherapy in treatment naïve type 2 diabetes patients Safety outcome Comparator 1 Comparator 2 I2 RR [95% CI] Number of events Number of events / / total subjects total subjects i. Empagliflozin + linagliptin vs empagliflozin monotherapy Empagliflozin + Empagliflozin linagliptin monotherapy ≥ 1 AE(s) 202/272 203/270 77% 0.99 [0.81, 1.21] ≥ 1 drug-related 37/272 38/270 0% 0.97 [0.64, 1.47] AE(s) ≥ 1 serious AE(s) 13/272 19/270 0% 0.68 [0.34, 1.35] Hypoglycaemia* 0/272 5/270 0% 0.18 [0.02, 1.56] UTI 32/272 25/270 29% 1.28 [0.70, 2.35] Events suggestive 12/272 13/270 9% 0.92 [0.40, 2.09] of genital infection i. Empagliflozin + linagliptin vs linagliptin monotherapy Empagliflozin + Linagliptin linagliptin monotherapy ≥ 1 AE(s) 202/272 97/135 0% 1.03 [0.91, 1.17] ≥ 1 drug-related 37/272 17/135 0% 1.08 [0.63, 1.84] AE(s) ≥ 1 serious AE(s) 13/272 2/135 0% 3.22 [0.74, 14.07] Hypoglycaemia* 0/272 1/135 NA 0.17 [0.01, 4.07] UTI 32/272 12/135 0% 1.32 [0.70, 2.49] Events suggestive 12/272 4/135 0% 1.45 [0.47, 4.47] of genital infection RR, relative risk; AE, adverse event; UTI, urinary tract infection.
    [Show full text]